De Los Reyes Emily C, Sharp Gregory B, Williams Jane P, Hale Sue E
University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, USA.
Pediatr Neurol. 2004 Apr;30(4):254-6. doi: 10.1016/j.pediatrneurol.2003.09.007.
Lennox-Gastaut syndrome is an epileptic encephalopathy characterized by multiple seizure types, mental retardation, and a slow spike-and-wave pattern on electroencephalography. Medical intractability is common. We identified a case series of six patients diagnosed with Lennox-Gastaut syndrome in which levetiracetam was initiated as add-on therapy for the management of seizures. At follow-up, four patients experienced 100% reduction of their myoclonic seizures; two patients had greater than 50% reduction of their atonic seizures, and four patients experienced 100% reduction in their generalized tonic-clonic seizures. Tonic seizures were not responsive to treatment. The most common side effect was irritability; the most positive change involved alertness. In this small sample, levetiracetam appeared effective in reducing seizures in Lennox-Gastaut syndrome. This preliminary study is limited by its retrospective design and small number of patients, but positive findings warrant a larger scale, multicenter study.
伦诺克斯-加斯托综合征是一种癫痫性脑病，其特征为多种发作类型、智力迟钝以及脑电图上的慢棘慢波图形。药物难治性很常见。我们确定了一组6例被诊断为伦诺克斯-加斯托综合征的病例，其中左乙拉西坦作为附加疗法开始用于癫痫发作的治疗。在随访中，4例患者的肌阵挛发作减少了100%；2例患者的失张力发作减少了50%以上，4例患者的全身强直阵挛发作减少了100%。强直发作对治疗无反应。最常见的副作用是易激惹；最积极的变化涉及警觉性。在这个小样本中，左乙拉西坦似乎对减少伦诺克斯-加斯托综合征的癫痫发作有效。这项初步研究受其回顾性设计和患者数量少的限制，但阳性结果值得进行更大规模的多中心研究。
